These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
203 related articles for article (PubMed ID: 3456787)
21. Carbohydrate antigen 19-9 (CA 19-9) and carcinoembryonic antigen (CEA) in pancreatic cancer. Role of age and liver dysfunction. Del Favero G; Fabris C; Panucci A; Basso D; Plebani M; Baccaglini U; Leandro G; Burlina A; Naccarato R Bull Cancer; 1986; 73(3):251-5. PubMed ID: 3530354 [TBL] [Abstract][Full Text] [Related]
22. Clinical evaluation of a new serum tumour marker CA 242 in pancreatic carcinoma. Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E Br J Cancer; 1992 May; 65(5):731-4. PubMed ID: 1316775 [TBL] [Abstract][Full Text] [Related]
23. Evaluation of serum pancreatic enzymes, carbohydrate antigen 19-9, and carcinoembryonic antigen in various pancreatic diseases. Satake K; Kanazawa G; Kho I; Chung Y; Umeyama K Am J Gastroenterol; 1985 Aug; 80(8):630-6. PubMed ID: 2411125 [TBL] [Abstract][Full Text] [Related]
24. CA 19-9 and carcinoembryonic antigen in pancreatic cancer diagnosis. Del Favero G; Fabris C; Plebani M; Panucci A; Piccoli A; Perobelli L; Pedrazzoli S; Baccaglini U; Burlina A; Naccarato R Cancer; 1986 Apr; 57(8):1576-9. PubMed ID: 3456255 [TBL] [Abstract][Full Text] [Related]
25. Measurement of a pancreatic cancer-associated antigen (DU-PAN-2) detected by a monoclonal antibody in sera of patients with digestive cancers. Sawabu N; Toya D; Takemori Y; Hattori N; Fukui M Int J Cancer; 1986 May; 37(5):693-6. PubMed ID: 3457770 [TBL] [Abstract][Full Text] [Related]
26. Serum levels of the carbohydrate antigen CA-50 in pancreatic disease. Blind PJ; Dahlgren ST Acta Chir Scand; 1987 Jan; 153(1):45-9. PubMed ID: 3472420 [TBL] [Abstract][Full Text] [Related]
27. Evaluation of carbohydrate antigens 19-9 and 12-5 in patients with pancreatic cancer. Pasquali C; Sperti C; D'Andrea AA; Bonadimani B; Del Favero G; Petrin P; Pedrazzoli S Pancreas; 1987; 2(1):34-7. PubMed ID: 3472197 [TBL] [Abstract][Full Text] [Related]
28. Comparative studies of DU-PAN-2, carcinoembryonic antigen, and CA19-9 in the serum and bile of patients with pancreatic and biliary tract diseases: evaluation of the influence of obstructive jaundice. Ohshio G; Manabe T; Watanabe Y; Endo K; Kudo H; Suzuki T; Tobe T Am J Gastroenterol; 1990 Oct; 85(10):1370-6. PubMed ID: 2220731 [TBL] [Abstract][Full Text] [Related]
29. [Is jaundice a cause of error in the interpretation of CA 19-9 blood levels?]. Nakad A; Colombel JF; Geubel AP; Cerulus G; Farchakh E; Degrez T; Janssen J; Cortot A; Paris JC; Dive C Acta Gastroenterol Belg; 1989; 52(1-2):17-22. PubMed ID: 2618531 [TBL] [Abstract][Full Text] [Related]
30. Multivariate analysis of six serum tumor markers (CEA, CA 50, CA 242, TPA, TPS, TATI) and conventional laboratory tests in the diagnosis of hepatopancreatobiliary malignancy. Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E Anticancer Res; 1995; 15(6B):2731-7. PubMed ID: 8669855 [TBL] [Abstract][Full Text] [Related]
31. Serum CA 19-9 concentrations and computed tomography findings in patients with pancreatic carcinoma. Sakahara H; Endo K; Nakajima K; Nakashima T; Koizumi M; Ohta H; Hidaka A; Kohno S; Nakano Y; Naito A Cancer; 1986 Apr; 57(7):1324-6. PubMed ID: 3456252 [TBL] [Abstract][Full Text] [Related]
32. [The tumor markers CA 19.9, Ca 50 and CEA in the differential diagnosis of pancreatic carcinoma]. Röthlin M; Metzger U; Joller H; Largiadèr F Schweiz Med Wochenschr; 1988 Jun; 118(24):924-9. PubMed ID: 2456610 [TBL] [Abstract][Full Text] [Related]
33. The influence of cholestasis on CA 50 and CA 242 in pancreatic cancer and benign biliopancreatic diseases. Pålsson B; Masson P; Andrén-Sandberg A Scand J Gastroenterol; 1993 Nov; 28(11):981-7. PubMed ID: 8284635 [TBL] [Abstract][Full Text] [Related]
34. Values of CA 19-9 in the serum, pure pancreatic juice, and aspirated pancreatic material in the diagnosis of malignant pancreatic tumor. Tatsuta M; Yamamura H; Iishi H; Ichii M; Noguchi S; Yamamoto R; Okuda S Cancer; 1985 Dec; 56(11):2669-73. PubMed ID: 3863691 [TBL] [Abstract][Full Text] [Related]
35. CA 19-9 assay in patients with extrahepatic cholestatic jaundice. Barone D; Onetto M; Conio M; Paganuzzi M; Saccomanno S; Aste H; Pugliese V Int J Biol Markers; 1988; 3(2):95-100. PubMed ID: 3243982 [TBL] [Abstract][Full Text] [Related]
37. Comparison of two newly identified tumor markers (CAR-3 and DU-PAN-2) with CA 19-9 in patients with pancreatic cancer. Ferrara C; Basso D; Fabris C; Malesci A; Fogar P; Meggiato T; Panozzo MP; Scalon P; Del Favero G; Plebani M Tumori; 1991 Feb; 77(1):56-60. PubMed ID: 1673269 [TBL] [Abstract][Full Text] [Related]
38. [CA 15-3 is present as a novel tumor marker in the sera of patients with breast cancer and other malignancies]. Gang Y; Adachi I; Ohkura H; Yamamoto H; Mizuguchi Y; Abe K Gan To Kagaku Ryoho; 1985 Dec; 12(12):2379-86. PubMed ID: 3865634 [TBL] [Abstract][Full Text] [Related]
39. Comparative effectiveness of the tumour diagnostics, CA 19-9, CA 125 and carcinoembryonic antigen in patients with diseases of the digestive system. Sakamoto K; Haga Y; Yoshimura R; Egami H; Yokoyama Y; Akagi M Gut; 1987 Mar; 28(3):323-9. PubMed ID: 3471687 [TBL] [Abstract][Full Text] [Related]
40. Tumour markers in pancreatic cancer. Haglund C; Kuusela P; Roberts PJ Ann Chir Gynaecol; 1989; 78(1):41-53. PubMed ID: 2667448 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]